Originally posted by NZ Trader
Abracadabra is required,, LCT instead of simply making a submission with evidence that substantiates the Primary End Point has been met ,,,LCT are going to plead a case,, on the info they have.. Would you yourself go out on a limb for LCT, are they so professional that you would implicitly take their word,,, History would demonstrate to me these guys have been reactive and not proactive..
Otherwise all companies that don't hit a primary end point would just plead a case... just look at FTT I can name 20 Biotechs that collapsed upon not hitting a primary end point,, Phase II is the Milestone and LCT didnt hit,, Medsafe stated there was no significant benefit to the Patient.
There may be the chance that the IP that LCT have could be of value to a much larger organisation , this should be a strategy that LCT are looking at , Travelling to shop around an exit on the Tech to a much larger Organisation but that again falls in the Business Realm , the longer you have to exit on a company/Product or Service the better your chances of completing a sale that will return something to shareholders,,
Be interesting to see the accounts again soon and monitor the burn rate,, I'm picking they must be light on Cash and the ASX Regs require 6 months operating Capital,, hey for $250k I'll shop the Technology around,, 3 month contract and Travel expenses, Just recently returned from Huston with a team that was exiting on some NZ IT compression software. So we know there are buyers for NZ Technology,, most Americans are amazed that Kiwi companies run on the smell of an oily rag.. and Tech development that costs 10's of millions in the States is completed in NZ in the low Millions...
Plenty of Stem Cell companies Globally that would love to own Imupel ,, as described, Currently just injecting Beneficial Cells directly to the effected site with the Human Immune system nailing 60% of the treatment as an infection... plus not having to lower the patients Immune system is a winner...
The Lab could have been coating treatments from Auckland to the world,,,
Is there Value in the IP you bet,,, can LCT extract that Value ,,, well thats why we are still here 2 years on,,,,???? do you think LCT have the Business Acumen to extract any $$ for the companys Tech,, or will it be sold with the Office Equipment??
Sorry, but I just wanted to clarify a point on the primary endpoint of the trial ...
As per the trial protocol (
https://clinicaltrials.gov/ct2/show/NCT02683629), the
sole primary outcome measure was :
"The safety of xenotransplantation of NTCELL as measured by the incidence of adverse events related to treatment [ Time Frame: up to 26 weeks ] ".
This primary outcome
has been achieved. There were no significant adverse effects.
The protocol also states that the various secondary outcomes were measured to 26 weeks and compared against the baseline .... the trial did not produce statistically significant improvements in this timeframe, which (in hindsight) was too short for the full benefits of the treatment to become apparent.
After 18 months, ""The principal investigator, Dr Barry Snow, Auckland City Hospital, says “The statistical improvement seen at 12 months has been sustained; variation between recipients is expected with the small number of subjects. The next step is further in-depth analysis to understand the data on all efficacy measurements both on and off normal symptomatic treatment.”"
http://www.lctglobal.com/upload/news/2018/181102 NTCELL Parkinsons 18 month.pdf
Looking forward to seeing the final results in June ...r
